OLVIG
BMRN icon

Oliver Lagore Vanvalin Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$4.37K – 742
2024
Q1 		$4.37K Hold
50
– – ﹤0.01% 529
2023
Q4 		$4.82K Hold
50
– – ﹤0.01% 529
2023
Q3 		$4.42K Hold
50
– – ﹤0.01% 578
2023
Q2 		$4.33K Hold
50
– – ﹤0.01% 582
2023
Q1 		$4.86K Hold
50
– – ﹤0.01% 489
2022
Q4 		$5.17K Hold
50
– – ﹤0.01% 464
2022
Q3 		$4K Sell
50
-94
-65% -$8.37K ﹤0.01% 446
2022
Q2 		$12K Hold
144
– – 0.01% 318
2022
Q1 		$11K Buy
+144
New +$12K 0.01% 315

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Oliver Lagore Vanvalin Investment Group's BMRN Position: Q2 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 50 shares — an estimated $4.37K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in BMRN in Q1 2022 and held it in 9 quarters. The position peaked at $12K in Q2 2022. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Oliver Lagore Vanvalin Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 50 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $4.37K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Oliver Lagore Vanvalin Investment Group's BioMarin Pharmaceuticals position peaked at $12K in Q2 2022.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2024, filed 15 Aug 2024.